News Roundup / Brazilian Pharma April 2020
Below we highlight recent news in Brazilian pharma, including the impact of coronavirus as well as legal and regulatory updates. Proposal to allow breaking of patents due to Covid-19…
Address: Av. Morumbi, 8264 – Brooklin CEP 04703-002 – São Paulo, SP,Brazil
Tel: (11) 2144-6911
Eli Lilly and Company, Lilly or simply, as it is known that the pharmaceutical industry of North America, has 134 years of existence. The company, with global operations and one of the largest funds applied research and development, is today one of the largest biotech companies in the world and owns brands that have become synonymous with ancient relief for diseases such as Prozac and Zyprexa Cialis, and prefers to characterized as a company that sells innovation in physical and mental health through medications that are usually the pioneers and most advanced in their therapeutic classes.
In Brazil, the company participates in the construction of the pharmaceutical market 66 years ago, and is one of the most important industries in the country, one of the leaders in the areas of mental health, oncology and women’s health.
Humulin, Humatrope, Humalog, Prozac, Gemzar , ReoPro, of Zyprexa, Evista, Xigris, of Cialis, Fort, Cymbalta and Byetta
Below we highlight recent news in Brazilian pharma, including the impact of coronavirus as well as legal and regulatory updates. Proposal to allow breaking of patents due to Covid-19…
Swiss pharma giant Novartis is teaming up with the Oswaldo Cruz Foundation (Fiocruz) in Brazil to conduct research throughout Latin America on neglected diseases. This agreement establishes an exchange…
Three seasoned pharma executives with a wealth of experience working in Brazil offer their insights on leadership strategies for success in the massive, but complex, Brazilian pharma market. …
Rodrigo Araujo of global organizational consulting firm Korn Ferry outlines what he sees as the leadership profile of the future – agile, digital, self-aware, and able to transform both themselves…
When combining the sheer size of Brazil – the fifth largest country in the world – with its tropical climate, its largely perfectible infrastructure, and the soaring importance of temperature…
“Brazil undoubtedly holds great development opportunities for the global pharmaceutical and healthcare industries,” boldly states Minister of Health Ricardo Barros, “and we hope to gain the trust of an increasing…
Maria del Pilar Muñoz, vice-president in charge of M&A and Sustainability at Eurofarma, one of the largest and most innovative pharmaceutical companies in Brazil with operations in 20 countries across…
Luciano Marques, president of Alcon Brazil, provides insights into recent investments and innovative initiatives aimed at strengthening Alcon’s relationships with its partners and customers in Brazil, and also documents the…
Armando Correa Lopes Jr, managing director of Siemens Healthineers Brazil, provides insights into the main trends and challenges at the core of Brazil’s healthcare discussion and documents the contribution of…
Tatiane Galindo, executive director of Ortosintese, Brazil’s and Latin America’s leading implant company, provides insights into Ortosintese’s historical commitment to the highest quality standards and her ambitions to further bolstering…
Fernando Itzaina, president and CEO of FQM Group, originally Farmoquímica, provides inspiring insights into the threefold development vision favored by this rapidly growing pharmaceutical company, his commitment to continue exploring…
Prof. Dr. Luiz Calistro Balestrassi, founder and president of NEUROTEC® – Biomedical Research & Development Company from Itajubá-MG, Brazil, and his daughter Esperança Balestrassi, Neurotec´s executive director, discuss the past,…
See our Cookie Privacy Policy Here